1.70
-14.14%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Seres Therapeutics
From its filings with the US Securities and Exchange Commission
Seres Therapeutics is based in Cambridge, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker MCRB. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $789,000 and net income of $5.7m. At that date it held total assets of $138.2m and shareholders' equity of $44.2m.
We are a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through discovery and development of novel live biotherapeutic product, or LBP, candidates. We led the successful development and approval of VOWST, the first FDA-approved orally administered microbiome biotherapeutic and a Breakthrough Therapy designated drug, which was sold to Société des Produits Nestlé S.A., or SPN, and with certain of its affiliates, collectively, Nestlé Health Science, in September 2024. We have established field-leading capabilities and platforms that are powered by best-in-field human data sets to advance a portfolio of products that can uniquely address diseases by targeting host pathways that are modulated by microbes in the human body, and, in particular, diseases associated with mucosal barrier-immune interface targets. We believe clinical and nonclinical data across our programs support the development of LBPs to target the prevention and treatment of a broad swath of infections, and to treat inflammatory and immune, or I&I, diseases. Our pipeline consists of SER-155, SER-603, and SER-147, as well as other potential candidates in earlier development.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 26 Jun 2015
- Employees
- 66
- Website
- serestherapeutics.com ↗
- Head office
- 200 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Stephen BerensonIndependent Chairman of the Board$187,267
- Ms. Marella ThorellCo-President, Co-Chief Executive Officer, Chief Financial Officer
- Mr. Thomas DesRosierCo-President, Co-Chief Executive Officer, Chief Legal Officer, Secretary$1.2m
- Dr. Matthew HennExecutive Vice President, Chief Scientific Officer$1.7m
- Dr. Teresa YoungExecutive Vice President, Chief Commercial and Strategy Officer$1.8m
- Dr. Dennis AusielloIndependent Director$140,258
- Mr. Paul BiondiIndependent Director$104,373
- Dr. Willard DereIndependent Director$116,873
- Dr. Claire FraserIndependent Director$116,873
- Mr. Kurt GravesIndependent Director$134,008
- Mr. Richard KenderIndependent Director$131,019
- Dr. Hans-Juergen WoerleIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 78
- Environment
- 83
- Social
- 99
- Governance
- 53
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Seres Therapeutics focuses on microbiome therapeutics platform for dysbiosis treatment.
- SER-109 is a lead product candidate for preventing Clostridium difficile infection recurrences.
- The company has 66 employees in the Health Care sector with a strong biotechnology focus.
Weaknesses
- The company has only 66 employees, which may limit operational capacity.
- Seres Therapeutics is based in Cambridge, Massachusetts, a high-cost location.
- The firm's IPO was in 2015, indicating a relatively short market presence.
Opportunities
- SER-262 is being developed to prevent initial CDI recurrences in the US market.
- SER-287 and SER-301 target inflammatory bowel disease in the Health Care sector.
- SER-155 aims to treat enteric bacterial pathogens in the biotechnology industry.
Threats
- Clostridium difficile infection remains a significant health challenge in the US.
- Competition in the microbiome therapeutics market is growing rapidly.
- The biotechnology sector faces regulatory hurdles for new drug approvals.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.